Sagimet Biosciences Inc.

Healthcare · Biotechnology · United States

Last price 10.43 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 739.58M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a...